Publications by authors named "Eva Caroff"

Claim this Profile
D
Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.
Emmanuel A Meyer, Andrew L Croxford, Carmela Gnerre, Paulina Kulig, Mark J Murphy, Eva Caroff

J Med Chem· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of a New Class of C5aR1 Antagonists Showing Activity.
Francis Hubler, Dorte Renneberg, Hervé Siendt, Simon Stamm, Kurt Hilpert, Eva Caroff

J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.
Emmanuel A Meyer, Päivi Äänismaa, Eric A Ertel, Eva Hühn, Daniel S Strasser, Eva Caroff

J Med Chem· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation.
Véronique Pons, Cédric Garcia, Naomi Tidten-Luksch, Aengus Mac Sweeney, Eva Caroff

Biochem Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.
Emmanuel A Meyer, Päivi Äänismaa, Sylvie Froidevaux, Marcel Keller, Luca Piali, Eva Caroff

J Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.
Eva Caroff, Emmanuel A Meyer, Päivi Äänismaa, Sylvie Froidevaux, Marcel Keller

J Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model.
Lydie Crescence, Roxane Darbousset, Eva Caroff, Francis Hubler, Markus A Riederer

Thromb Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects.
Mike Ufer, Christine Huynh, Jan Jaap van Lier, Eva Caroff, Hartmut Fischer

Xenobiotica· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The reversible P2Y antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat.
Markus Rey, Markus Kramberg, Patrick Hess, Keith Morrison, Roland Ernst, Eva Caroff

Pharmacol Res Perspect· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel.
Eva Caroff, Francis Hubler, Emmanuel Meyer, Dorte Renneberg, Carmela Gnerre

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation.
Eva Caroff, Emmanuel Meyer, Alexander Treiber, Kurt Hilpert, Markus A Riederer

Bioorg Med Chem Lett· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The isomerisation of (Z)-3-[2H1]-phenylprop-2-enone as a measure of the rate of hydroperoxide addition in Weitz-Scheffer and Julia-Colonna epoxidations.
David R Kelly, Eva Caroff, Robert W Flood, William Heal, Stanley M Roberts

Chem Commun (Camb)· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis